Relative efficacy of drugs: an emerging issue between regulatory agencies and third-party payers
- 26 February 2010
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Drug Discovery
- Vol. 9 (4), 277-291
- https://doi.org/10.1038/nrd3079
Abstract
Drug regulatory agencies have traditionally assessed the quality, safety and efficacy of drugs, and the current paradigm dictates that a new drug should be licensed when the benefits outweigh the risks. By contrast, third-party payers base their reimbursement decisions predominantly on the health benefits of the drug relative to existing treatment options (termed relative efficacy; RE). Over the past decade, the role of payers has become more prominent, and time-to-market no longer means time-to-licensing but time-to-reimbursement. Companies now have to satisfy the sometimes divergent needs of both regulators and payers, and to address RE during the pre-marketing stages. This article describes the current political background to the RE debate and presents the scientific and methodological challenges as they relate to RE assessment. In addition, we explain the impact of RE on drug development, and speculate on future developments and actions that are likely to be required from key players.Keywords
This publication has 43 references indexed in Scilit:
- Clinical Trials Design Lessons From the CATIE StudyAmerican Journal of Psychiatry, 2009
- Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviewsBMJ, 2009
- Limits on Medicare's Ability to Control Rising Spending on Cancer DrugsNew England Journal of Medicine, 2009
- Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemmaNature Reviews Drug Discovery, 2008
- Coverage With Evidence DevelopmentMedical Care, 2008
- Stellungnahme der AG Methoden der gesundheitsökonomischen Evaluation (AG MEG) zu dem Methodenpapier „Methodik für die Bewertung von Verhältnissen zwischen Nutzen und Kosten im System der deutschen gesetzlichen Krankenversicherung“ des Instituts für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)Das Gesundheitswesen, 2008
- Why Olanzapine Beats Risperidone, Risperidone Beats Quetiapine, and Quetiapine Beats Olanzapine: An Exploratory Analysis of Head-to-Head Comparison Studies of Second-Generation AntipsychoticsAmerican Journal of Psychiatry, 2006
- EMEA and the evaluation of health-related quality of life data in the drug regulatory process.International Journal of Technology Assessment in Health Care, 2004
- Network meta‐analysis for indirect treatment comparisonsStatistics in Medicine, 2002
- Users' Guides to the Medical LiteraturePublished by American Medical Association (AMA) ,1999